Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body’s immune system attacks the
peripheral nerves. It often begins after an infection, such as a respiratory or gastrointestinal infection, and can lead to
muscle weakness and paralysis.
The symptoms of GBS usually start with weakness and tingling in the legs and can progress to muscle weakness,
affecting both sides of the body. In severe cases, it can cause total paralysis, including the respiratory muscles, which
may require mechanical ventilation. The progression of symptoms typically peaks within 2-4 weeks after onset.
The exact cause of Guillain-Barré syndrome is not fully understood, but it is often triggered by infections, particularly
viral or bacterial infections. The most common trigger is a bacterial infection called Campylobacter jejuni, but it can
also be triggered by viruses like the flu, Zika virus, and others.
Diagnosis is based on clinical symptoms, medical history, and tests such as lumbar puncture (to check for elevated
protein levels in the cerebrospinal fluid) and nerve conduction studies (to assess nerve function).
Treatment for GBS typically involves hospitalization and supportive care. The main treatments include intravenous
immunoglobulin (IVIG) therapy or plasmapheresis, which help reduce the immune system’s attack on the nervous
system. Physical therapy may be needed to help with recovery of strength and mobility.
Most individuals with Guillain-Barré syndrome begin to recover within weeks to months, though some may
experience long-term effects, such as weakness or sensory changes. The cause of GBS-related nerve damage and
the extent of recovery can vary from person to person. Early diagnosis and treatment can improve the chances of a
full recovery.